Antiviral drug

ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Funding Round

Retrieved on: 
Tuesday, June 15, 2021
Sarbecovirus, Respiratory diseases, Medical specialties, Animal diseases, COVID-19, Occupational safety and health, Public health, Zoonoses, Severe acute respiratory syndrome, Antiviral drug, TLR2

The new financing will advance INNA-051, ENA Respiratorys lead clinical candidate being developed to activate innate immunity in the nose, the primary site of most respiratory virus infections including COVID-19.

Key Points: 
  • The new financing will advance INNA-051, ENA Respiratorys lead clinical candidate being developed to activate innate immunity in the nose, the primary site of most respiratory virus infections including COVID-19.
  • The milestone-based financing round was jointly led by Australian life science investors Brandon Capital Partners and Minderoo Foundation, with co-investment from Uniseed.
  • We recognize that in addition to vaccines, the world needs safe, convenient, broad-spectrum anti-viral therapies to win the fight against COVID-19, said Chris Smith, Ph.D., Chairman of ENA Respiratory.
  • Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model.

Cidara Therapeutics to Participate in the Raymond James Human Health Innovation Conference

Retrieved on: 
Monday, June 14, 2021
Biocides, Antiviral drug

SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, and James Levine, Chief Financial Officer, will participate in investor meetings at the Raymond James Human Health Innovation Conference, being held virtually June 21-23, 2021.

Key Points: 
  • SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, and James Levine, Chief Financial Officer, will participate in investor meetings at the Raymond James Human Health Innovation Conference, being held virtually June 21-23, 2021.
  • Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections.
  • The Companys portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to AVCs for the prevention and treatment of influenza and other viral diseases from Cidaras proprietary Cloudbreak antiviral platform.
  • Cidara is headquartered in San Diego, California.

Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential HIV Cure

Retrieved on: 
Monday, June 14, 2021
Life sciences, Health sciences, Natural sciences, Antiviral drug, Biocides, HIV, Biopharmaceutical, Therapy

Dr. Serhat Gumruku, co-founder and inventor of Enochian BioSciences, and Director of Seraph Research Institute (SRI), submitted the Pre-IND.

Key Points: 
  • Dr. Serhat Gumruku, co-founder and inventor of Enochian BioSciences, and Director of Seraph Research Institute (SRI), submitted the Pre-IND.
  • The request was based on the results of a 54-year old man living with HIV who had failed to suppress the virus with antiviral therapy.
  • Enochian BioSciences, Inc. is a biopharmaceutical company dedicated to identifying, developing, manufacturing, and commercializing gene-modified cell therapy.
  • There is no assurance the findings will result in an effective alternative treatment for HIV.

Adamis Provides Update on Clinical Trial Start-Up Progress for Tempol in the Treatment of COVID-19

Retrieved on: 
Friday, June 11, 2021
Medical specialties, Health, Clinical medicine, Respiratory syncytial virus, Syncytial virus, COVID-19, Antiviral drug, Asthma

In addition to safety, the study will examine markers of inflammation, symptoms, and the rate of hospitalization for patients taking Tempol versus placebo.

Key Points: 
  • In addition to safety, the study will examine markers of inflammation, symptoms, and the rate of hospitalization for patients taking Tempol versus placebo.
  • The clinical trial start-up activities follow recently published work by the National Institutes of Health (NIH), which has identified Tempol as a potentially potent antiviral for COVID-19.
  • The addition of a well-respected data safety monitoring board to the well-designed trial should further increase the likelihood of meaningful clinical data.
  • Adamis has a worldwide license to use Tempol for the treatment of respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19.

Antios Therapeutics Announces Poster Presentation at the Inaugural HBV-TAG Conference

Retrieved on: 
Friday, June 11, 2021
Antiviral drug, Biocides, Hepatitis

Systemic and hepatic concentrations of both clevudine and its phosphoramidate prodrug, ATI-2173, were evaluated in two animal models.

Key Points: 
  • Systemic and hepatic concentrations of both clevudine and its phosphoramidate prodrug, ATI-2173, were evaluated in two animal models.
  • ATI-2173 demonstrated potent antiviral activity in vitro as a monotherapy, and additive or synergistic activity with traditional nucleos(t)ides and other direct-acting antivirals.
  • The PK profile was dose-proportional with Cmax well-below the Cmin reported with clevudine administration at the marketed 30 mg dose.
  • Antios is currently developing ATI-2173, aiming to provide chronic hepatitis B-infected patients with a curative combination regimen.

Novan Reports Positive Topline Results from Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum

Retrieved on: 
Friday, June 11, 2021
Health sciences, Health, Molluscum contagiosum, Poxviruses, Clinical research, Pharmaceutical industry, Life sciences, Drug discovery, Antiviral drug, Clinical trial, Molluscum contagiosum virus

Consistent with results from the Companys Phase 2 and earlier Phase 3 studies, SB206 was found to be safe and well tolerated.

Key Points: 
  • Consistent with results from the Companys Phase 2 and earlier Phase 3 studies, SB206 was found to be safe and well tolerated.
  • These results are a testament to Novans solid execution of the SB206 clinical program and strategy, and our belief in the potential of SB206 to provide patients with treatment benefit.
  • There are currently no U.S. Food and Drug Administration (FDA) approved therapies for the treatment of molluscum.
  • The Companys lead product candidate, SB206, a topical antiviral gel, for the treatment of molluscum contagiosum, is currently being evaluated in the B-SIMPLE4 pivotal Phase 3 clinical study.

Cocrystal Pharma’s Participation in the Noble Capital Markets C-Suite Interview Series is Now Available Online

Retrieved on: 
Wednesday, June 9, 2021
Cocrystal, Crystallography, Solid-state chemistry, Antiviral drug

During the 30-minute video int e rview hosted by Noble Capital Markets Senior Equity Research Analyst Robert LeBoyer, Cocrystal discussed its antiviral drug-discovery and development work and provided program updates.

Key Points: 
  • During the 30-minute video int e rview hosted by Noble Capital Markets Senior Equity Research Analyst Robert LeBoyer, Cocrystal discussed its antiviral drug-discovery and development work and provided program updates.
  • Cocrystal utilizes a proprietary structure-based technology platform to discover viral inhibitors that address underserved medical needs in very large markets including pandemics and widespread viral infections, said Sam Lee, Ph.D., interim co-CEO and President.
  • This powerful platform differentiates Cocrystals approach and allows us to focus on three important drug-discovery processes including improvements with in vitro potency, broad-spectrum activity and drug-resistance profile.
  • Given our cost-efficient structure and financial resources, we believe we have sufficient capital to fund current operations and planned program activities through 2024.

Selva Announces SLV213, a Potential Oral COVID-19 Treatment, Has Broad Activity Against SARS-CoV-2 Variants of Concern

Retrieved on: 
Wednesday, June 9, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Hospitals, Clinical trials, Respiratory diseases, Animal diseases, Health, Antiviral drug, Biocides, COVID-19, Severe acute respiratory syndrome

No loss of potency was found and equal activity against all variants was determined, explained Felix Frueh, Ph.D., Chief Scientific Officer of Selva.

Key Points: 
  • No loss of potency was found and equal activity against all variants was determined, explained Felix Frueh, Ph.D., Chief Scientific Officer of Selva.
  • SLV213 has demonstrated activity against SARS-CoV-2 in vitro and in vivo and completed a Phase 1 clinical trial for safety.
  • As an oral antiviral, SLV213 has the potential to fill a critical gap in the treatment landscape for COVID-19.
  • Selva previously reported that SLV213 successfully completed a Phase 1 ascending oral dose clinical trial in healthy subjects.

Sorrento Announces Positive Results From Its License Partner, Kelun, on a Phase I Study of Safety and Pharmacokinetics of A166, a Novel HER2 ADC for Advanced HER2 Positive Breast Cancers

Retrieved on: 
Friday, June 4, 2021
Health sciences, Life sciences, Applied sciences, Drug discovery, Radicular pain, Antiviral drug, Osteoarthritis, Therapy

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19.

Key Points: 
  • Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19.
  • Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIGUARD, COVI-AMG, COVISHIELD, Gene-MAb, COVI-MSC and COVIDROPS; and diagnostic test solutions, including COVITRACK, COVISTIX and COVITRACE.
  • RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients.
  • SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica.

TNO Study Shows Efficacy of Corona Canon Against Covid-19

Retrieved on: 
Friday, June 4, 2021
Sarbecovirus, Respiratory diseases, Animal diseases, Medical specialties, Corona, Biocides, Zoonoses, Severe acute respiratory syndrome, Antiviral drug, COVID-19

RIJSWIJK, Netherlands, June 4, 2021 /PRNewswire/ --The Scalene Hypercharge Corona Canon (Shycocan) can be used effectively to neutralize Covid-19 and other corona viruses in closed spaces.

Key Points: 
  • RIJSWIJK, Netherlands, June 4, 2021 /PRNewswire/ --The Scalene Hypercharge Corona Canon (Shycocan) can be used effectively to neutralize Covid-19 and other corona viruses in closed spaces.
  • Research by TNO1shows that the corona canon reduces the SARS COV-2 virus on stainless steel surfaces by 94.9 percent within fifteen minutes.
  • In the Netherlands, some schools, hair salons and a funeral home are already working with the corona canon.
  • That is why we are pleased that TNO has successfully demonstrated the antiviral effect of the Shycocan," says Jongbloed.